Liraglutide augments weight loss in pre-type 2 diabetes

August 15, 2013
Liraglutide augments weight loss in pre-type 2 diabetes
For patients at high risk of type 2 diabetes mellitus and cardiovascular disease, liraglutide in additional to calorie restriction is associated with more weight loss and improvements in insulin resistance, glucose tolerance, and some cardiovascular disease risk factors, according to a study published online July 8 in Diabetes Care.

(HealthDay)—For patients at high risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), liraglutide in additional to calorie restriction is associated with more weight loss and improvements in insulin resistance, glucose tolerance, and some CVD risk factors, according to a study published online July 8 in Diabetes Care.

Sun H. Kim, M.D., from the Stanford University School of Medicine in California, and colleagues randomized 68 older individuals (mean age, 58 years) with overweight/obesity and prediabetes to receive liraglutide (35 patients) or placebo (33 patients) for 14 weeks. Participants were advised to lower calorie intake by 500 kcal/day. Measurement of the steady-state (SSPG) concentration during the insulin suppression test was used to quantify peripheral ; inflammatory markers and traditional CVD risk factors were also evaluated.

Eleven individuals assigned to liraglutide and six assigned to placebo discontinued the study. The researchers found that weight loss was significantly higher for those who continued to use liraglutide (6.8 kg) versus placebo (3.3 kg). There were also significant improvements in SSPG concentration and significantly greater lowering of systolic blood pressure, fasting glucose, and triglyceride concentration among liraglutide-treated subjects. Pulse increased significantly after liraglutide treatment, but inflammatory markers were similar in the two groups.

"The addition of liraglutide to calorie restriction significantly augmented weight loss and improved insulin resistance, systolic blood pressure, glucose, and triglyceride concentration in this population at high risk for development of T2DM and CVD," the authors write.

Liraglutide and matching placebo were provided by Novo Nordisk.

Explore further: Injected liraglutide is better than oral sitagliptin for blood glucose control in type 2 diabetes

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Genetic risk score linked to increased risk of diabetes

July 30, 2013

(HealthDay)—A genetic risk score based on 46 gene variants linked to type 2 diabetes is associated with increases in the risk of type 2 diabetes and declines in glucose control and beta-cell function, according to a study ...

Recommended for you

Diets avoiding dry-cooked foods can protect against diabetes

August 24, 2016

Simple changes in how we cook could go a long way towards preventing diabetes, say researchers at the Icahn School of Medicine at Mount Sinai. A new randomized controlled trial, published online July 29 in the journal Diabetologia, ...

New study reveals a novel protein linked to type 2 diabetes

August 16, 2016

Findings from Boston University School of Medicine (BUSM), which appear in eLife, provide a possible explanation as to why most people who are obese develop insulin resistance and type 2 diabetes. A minority of obese individuals, ...

Gene variant explains differences in diabetes drug response

August 9, 2016

The first results from a large international study of patients taking metformin, the world's most commonly used type 2 diabetes drug, reveal genetic differences among patients that may explain why some respond much better ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

purasilk
not rated yet Aug 15, 2013
The best way to lose weight fast is http://tinyurl.com/onljzp6

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.